An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients
Status: | Terminated |
---|---|
Conditions: | Chronic Obstructive Pulmonary Disease |
Therapuetic Areas: | Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 20 - 75 |
Updated: | 4/21/2016 |
Start Date: | April 2015 |
End Date: | August 2015 |
A 2-Stage, Single-Dose Study in Healthy Volunteers and COPD Patients With an Open Label Ipratropium Bromide Reference to Evaluate the Efficacy, Pharmacokinetics, and Safety Profile of Inhaled TV48108
The primary objective of the study is to characterize the safety profile and duration of
bronchodilation of a single dose of inhaled TV48108.
bronchodilation of a single dose of inhaled TV48108.
Inclusion Criteria:
Stage 1 (Healthy Volunteers)
- Male or female 20 to 75 years of age, inclusive, weighing 50 to 80 kg with a body
mass index (BMI) of less than 30 kg/m^2.
- In good health as determined by medical and psychiatric history, physical
examination, electrocardiogram (ECG), serum chemistry, hematology, urinalysis, and
serology.
- Other criteria apply, please contact the investigator for more information
Stage 2 (Chronic Obstructive Lung Disease (COPD) patients)
- Male or female; 40 to 75 years of age, inclusive with a minimum body weight of 40 kg
- Current or former cigarette smokers with a history of cigarette smoking of ≥10 pack
years at the screening visit
- Diagnosis of COPD as defined by the Global Initiative for Chronic Obstructive Lung
Disease guidelines.
- Other criteria apply, please contact the investigator for more information
Exclusion Criteria:
Stage 1 (Healthy Volunteers)
- History or current evidence of a clinically significant or uncontrolled disease
- Any disorder that may interfere with the absorption, distribution, metabolism or
excretion of study drugs.
- History of severe allergy to milk protein
- Active smokers or former smokers who quit within 3 months of the first dose of study
drug. Former smokers with greater than five-pack years (ie, the equivalent of one
pack per day for five years) are also excluded.
- Other criteria apply, please contact the investigator for more information
Stage 2 (Chronic Obstructive Lung Disease (COPD) patients)
- Recent history of hospitalization due to an exacerbation of airway disease within 3
months
- Need for increased treatments of COPD within 6 weeks prior to the screening visit
- History of and/or current diagnosis of asthma
- Known α1 antitrypsin deficiency, active lung infections (such as tuberculosis or
pneumonia), and lung cancer are absolute exclusionary conditions
- Other criteria apply, please contact the investigator for more information
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials